Diphenoxyphosphanolate | 102-10-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Diphenoxyphosphanolate
• 英文别名: diphenyl phosphite
• CAS: 102-10-3
• 化学式: C12H10O3P-
• 分子量: 233.18
• InChiKey: KUMNEOGIHFCNQW-UHFFFAOYSA-N

物化性质

• 沸点：
  150-152 °C(Press: 1 Torr)
• 密度：
  1.2318 g/cm3
• 熔点：
  25 °C

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  二聚氰胺 、 Diphenoxyphosphanolate 在 氮气 作用下， 反应 4.0h， 以to obtain DPP-DICY (P-12)的产率得到Dpp dicy
  参考文献：
  名称：

  Phosphorus-containing flame-retardant hardeners, epoxy resins, advanced epoxy resins and cured epoxy resins

  摘要：

  本发明公开了一种含活性氢的磷化合物，用于交联树脂并赋予固化树脂阻燃性，特别是通过活性氢与环氧基团之间的加成反应，将固化剂与二元或多元环氧树脂反应制备的固化阻燃环氧树脂。本发明还公开了由含活性氢的磷化合物和环氧氯丙烷制备的环氧树脂。

  公开号：

  US20030120021A1

文献信息

• Method and compositions for identifying anti-HIV therapeutic compounds
  申请人：Arimilli N. Murty

  公开号：US20050239054A1

  公开（公告）日：2005-10-27

  Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

  提供了一种识别具有羧酸酯或膦酸酯基团的抗HIV治疗化合物的方法。可以使用新型酶GS-7340酯水解酶筛选这些化合物的库。还提供了与GS-7340酯水解酶相关的组合物和方法。
• Process for production of carboxylic acid aryl esters
  申请人：——

  公开号：US20020013491A1

  公开（公告）日：2002-01-31

  A process for production of carboxylic acid aryl esters which comprises reacting a carboxylic acid having at least one carboxyl group with a di- or tri-aryl phosphite compound, in the presence of a basic compound and/or water. The carboxylic acid aryl esters can also be produced by reacting a carboxylic acid or a basic salt thereof with a diaryl phosphite compound.

  一种生产羧酸芳基酯的方法，包括在碱性化合物和/或水的存在下，将至少含有一个羧基的羧酸与二芳基磷酸酯化合物或三芳基磷酸酯化合物反应。也可以通过将羧酸或其碱性盐与二芳基磷酸酯化合物反应来生产羧酸芳基酯。
• Process for preparing N-tritylimidazole compounds
  申请人：Sumitomo Chemical Company, Limited

  公开号：US04216333A1

  公开（公告）日：1980-08-05

  A process for preparing N-tritylimidazole compounds of the formula: ##STR1## by the reaction between a tritylcarbinol derivative of the formula: ##STR2## and an imidazole derivative of the formula: ##STR3## , characterized in that the reaction is effected in the presence of a phosphorus compound of the formula: ##STR4##

  一种制备式为：##STR1## 的N-三苯甲基咪唑化合物的方法，通过式为：##STR2## 的三苯甲基甲醇衍生物和式为：##STR3## 的咪唑衍生物之间的反应，其特征在于在式为：##STR4## 的磷化合物存在下进行反应。
• Inhibitors and substrates of thrombin
  申请人：Thrombosis Research Institute

  公开号：US05648338A1

  公开（公告）日：1997-07-15

  Peptides which act as inhibitors or substrates of thrombin are derived from the formula: D-Phe-Pro-Arg or its analogues, wherein Phe is substituted by (a), wherein Ar.sub.1 or Ar.sub.2 are the same or different and are selected from the group consisting of phenyl, thienyl, pyridyl, naphthyl, thionaphtyl, indolyl and saturated groups corresponding to these, optionally substituted by up to three groups selected from C.sub.1 -C.sub.3 alkyl and C.sub.1 -C.sub.3 alkoxy, L.sub.1 and L.sub.2 are the same of different and are selected from the group consisting of CH.sub.2, C.sub.2 --C.sub.2, O-CH.sub.2, S-CH.sub.2, Ar-L taken together optionally means H, diphenyl-methyl, fluorenyl or saturated groups corresponding to these, but one of the Ar-L cannot be H when the other [CH.sub.2 ].sub.n -Q, (c) where Q=H, amino, amidino, imidazole, guanidino or isothioureido and n=1-5, preferably 3-5, or C.sub.3 -C.sub.9 alkyl and C.sub.5 -C.sub.10 aryl or alkylaryl optionally substituted by up to three groups selected from hydroxy and C.sub.1 -C.sub.4 alkoxy; Z=CN, COR.sub.1, (d) or (e), where R.sub.1 =H, OH, CH.sub.2 Cl, CH.sub.2 --C.sub.2 --CO--pip, CF.sub.2 --CF.sub.2 --CO--pip, (f), (g), CH.sub.2 --C.sub.2 --CO--Pro--NHEt, CF.sub.2 --CF.sub.2 --CO--Pro--NHEt or a chromophoric group e.g. pHA, MCA, R.sub.2 and R.sub.3 are the same or different and are selected from the group consisting of OH, OR.sub.6 and NR.sub.6 R.sub.7, or R.sub.2 and R.sub.3 taken together represent the residue of a diol; where R.sub.6 and R.sub.7, which are the same or different, are C.sub.1 -C.sub.10 alkyl, phenyl or C.sub.6 -C.sub.10 arylalkyl, R.sub.4 and R.sub.5 are the same or different and are selected from R.sub.2, R.sub.3, Gly-pip, Ala-pip or Gly-Pro-NHEt.

  抑制或作为凝血酶底物的肽来自于公式：D-Phe-Pro-Arg或其类似物，其中Phe被(a)代替，其中Ar.sub.1或Ar.sub.2相同或不同，选自苯基，噻吩基，吡啶基，萘基，噻萘基，吲哚基和相应饱和基团，可选择性地取代最多三个来自C.sub.1-C.sub.3烷基和C.sub.1-C.sub.3烷氧基的基团，L.sub.1和L.sub.2相同或不同，选自CH.sub.2，C.sub.2--C.sub.2，O-CH.sub.2，S-CH.sub.2，Ar-L共同取决于H，二苯甲基，芴基或相应饱和基团，但当另一个[CH.sub.2].sub.n-Q时，其中一个Ar-L不能为H，(c)，其中Q=H，氨基，酰胺基，咪唑基，胍基或异硫脲基，n=1-5，优选3-5，或C.sub.3-C.sub.9烷基和C.sub.5-C.sub.10芳基或烷基芳基，可选择性地取代最多三个羟基和C.sub.1-C.sub.4烷氧基的基团；Z=CN，COR.sub.1，(d)或(e)，其中R.sub.1=H，OH，CH.sub.2Cl，CH.sub.2--C.sub.2--CO--pip，CF.sub.2--CF.sub.2--CO--pip，(f)，(g)，CH.sub.2--C.sub.2--CO--Pro--NHEt，CF.sub.2--CF.sub.2--CO--Pro--NHEt或色团基，例如pHA，MCA，R.sub.2和R.sub.3相同或不同，选自OH，OR.sub.6和NR.sub.6R.sub.7，或R.sub.2和R.sub.3共同代表二醇残基；其中R.sub.6和R.sub.7，相同或不同，为C.sub.1-C.sub.10烷基，苯基或C.sub.6-C.sub.10芳基烷基，R.sub.4和R.sub.5相同或不同，选自R.sub.2，R.sub.3，Gly-pip，Ala-pip或Gly-Pro-NHEt。
• Phosphono/biaryl substituted amino acid derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05250522A1

  公开（公告）日：1993-10-05

  The present invention relates to the N-phosphonomethyl-biaryl substituted amino acid derivatives of formula I ##STR1## wherein X represents a direct bond, C.sub.1-4 -alkylene or C.sub.2 -C.sub.4 -alkenylene; R and R' represent independently hydrogen, carbocyclic aryl, 6-tetrahydronaphthyl, 5-indanyl, .alpha.-(trichloromethyl, carboxyl, esterified carboxyl or amidated carboxyl)substituted-(lower alkyl or aryl-lower alkyl), acyloxymethyl optionally monosubstituted on methyl carbon by C.sub.1-20 -alkyl, by C.sub.5 -C.sub.7 -cycloalkyl, by aryl or by aryl-lower alkyl; R.sub.1 represents monocyclic carbocyclic or monocyclic heterocyclic aryl; COR.sub.3 represents carboxyl or carboxyl derivatized in form of a pharmaceutically acceptable ester; R.sub.2 and R.sub.4 represent hydrogen, lower alkyl, trifluoromethyl, lower alkoxy or halogen; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.

  本发明涉及公式I的N-磷酸甲基-联苯基取代氨基酸衍生物，其中X代表直接键，C.sub.1-4-烷基或C.sub.2-C.sub.4-烯基; R和R'分别独立表示氢、环烷基芳基、6-四氢萘基、5-茚基、α-(三氯甲基、羧基、酯化羧基或酰胺化羧基)取代-(较低烷基或芳基-较低烷基)、酰氧甲基在甲基碳上选择性地单取代C.sub.1-20-烷基、C.sub.5-C.sub.7-环烷基、芳基或芳基-较低烷基; R.sub.1表示单环芳基或单环杂环芳基; COR.sub.3表示羧基或以药学上可接受的酯形式衍生的羧基; R.sub.2和R.sub.4表示氢、较低烷基、三氟甲基、较低烷氧基或卤素;及其药学上可接受的盐;包含所述化合物的制药组合物;制备所述化合物和中间体的方法;以及通过将所述化合物用于需要此类治疗的哺乳动物的治疗中，抑制中性内肽酶的方法。